Alemtuzumab (campath ) (DrugBank: Alemtuzumab)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
60 | Aplastic anemia | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00195624 (ClinicalTrials.gov) | September 15, 2005 | 16/9/2005 | Alemtuzumab to Treat Severe Aplastic Anemia | A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia | Severe Aplastic Anemia, Refractory;Severe Aplastic Anemia, Relapse | Biological: Alemtuzumab (Campath );Drug: Cyclosporine | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | 2 Years | 110 Years | All | 47 | Phase 2 | United States |